| Revenue growth | 23.6% YoY revenue growth; crossed ₹1,000cr quarterly revenue mark. |
|---|---|
| Margins | Temporary 150bps hit due to GTM investments; recovery by H2FY27. |
| Demand visibility | Strong; 5-8% industry CAGR through 2028 with GenAI tailwinds. |
| Management confidence | High; shifted from 'cautiously optimistic' to 'excited and confident'. |
Growth
Revenue grew 23.6% YoY in INR terms (18.2% USD), driven by strategic deepening with Top-20 pharma and scaling mid-market clients.
Outlook
Management expects EBITDA margin recovery in H2FY27 as aggressive AI and GTM investments are fully absorbed.
Risks
₹20.3cr provision for a US class-action lawsuit and significant forex volatility charges impact near-term bottom-line quality.
Earnings Call filed with NSE, NSE: INDGN. Summary written with AI assistance from the document.
Indegene Ltd: key numbers
- Share price
- ₹605.45
- Market cap
- ₹14,586 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 36.4×Sector 53.1×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 9.92%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Business Update
Indegene Limited hosted its Indegene Digital Summit 2026, focusing on operationalizing AI within life sciences. The event also featured the presentation of the VITAL Awards 2026.
Indegene Merger & Restructuring
Indegene Limited completed the internal merger of its two indirect wholly owned subsidiaries in Germany. This reorganization does not impact Indegene's financial position or operations.
Indegene Legal & Regulatory
Indegene Limited received preliminary court approval for a class action settlement related to the U.S. Telephone Consumer Protection Act. Final hearing is scheduled for January 2027.
Indegene Legal & Regulatory
The U.S. Court preliminarily approved the class action settlement for Indegene's subsidiary. The maximum settlement fund is approximately ₹44.84 Crore.
- Value
- ₹44.84 Cr
Indegene Legal & Regulatory
Indegene Limited's subsidiary, Indegene Inc., finalized a class-action settlement framework regarding U.S. fax communication violations. The maximum potential settlement fund is USD 4.72 million (₹44.84 Crore).
- Value
- ₹44.84 Cr
Indegene Legal & Regulatory
Indegene Limited's subsidiary finalized a USD 4.72 million class-action settlement agreement regarding U.S. TCPA violations. The settlement, involving approximately 18,851 unique fax numbers, remains subject to court approval.
- Value
- ₹45.24 Cr